The novel mechanism of anticancer effect on gastric cancer through inducing G0/G1 cell cycle arrest and caspase-dependent apoptosis in vitro and in vivo by methionine enkephalin

Xiaonan Wang1
Jing Tian1
Xue Jiao2
Jin Geng3
Reizhe Wang4
Ning Liu5
Xinghua Gao6
Noreen Griffin7
Yuan Gao8
Fengping Shan1

1Department of Immunology, College of Basic Medical Science, China Medical University, Shenyang, China; 2Department of Ophthalmology, China Medical University, Shenyang, China; 3Department of Translational Medicine, No. 4 Teaching Hospital, China Medical University, Shenyang, China; 4Department of Gynecology, Department of Ophthal-mology, China Medical University, Shenyang, China; 5Department of Gynecologic Oncology, No. 1 Teaching Hospital, China Medical University, Shenyang, China; 6Department of Gynecologic Oncology, Shengjing Hospital, Department of Dermatology, No. 1 Teaching Hospital, China Medical University, Shenyang, China; 7Immune Therapeutics, Inc., Orlando, FL, USA; 8Faculty of Information and Engineering, Northeastern University, Shenyang, China

Correspondence: Fengping Shan
Department of Immunology, College of Basic Medical Science, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Tel +86 189 0091 1546
Fax +86 248 660 4452
Email fpshan@cmu.edu.cn

Background: Gastric cancer (GC) is the second cause of cancer-related deaths. Methionine enkephalin (MENK), an endogenous opioid peptide, has immunological and antitumor activity.

Purpose: The aim of this work was to investigate whether MENK could exhibit activity against human GC in vitro and in vivo.

Materials and methods: Human GC cells were treated with MENK. Cell viability, colony formation, cell morphology, cell cycle, and apoptosis were assessed. The effects of MENK on gene expression of OGFr, Bax, BCL-2, caspase-3, PARP, Ki67, cyclin D1, c-myc, survivin were quantified by qRT-PCR. Western blot was used to analyze the effects of MENK on protein expression of OGFr, Bax, BCL-2, caspase-3, PARP. The anti-tumor activity of MENK in gastric carcinoma was also investigated with animal experiments.

Results: The results indicate that MENK could significantly inhibit the growth of human GC cells SGC7901 and HGC27 in a concentration- and time-dependent manner, decrease the number of cell colonies, and arrest cell cycle in the G0/G1 phase by causing a decrease in Ki67, cyclin D1, and c-myc mRNA. Furthermore, MENK could induce tumor cell apoptosis associated with the upregulation of Bax, a corresponding downregulation of BCL-2 and survivin, and activation of caspase-3 and PARP. Moreover, MENK upregulated the expression of opioid receptors (OGFr) in SGC7901 and HGC27 cells. The interaction between MENK and OGFr in SGC7901 and HGC27 cells appears to be essential for the antitumor activity of MENK.

Conclusion: We conclude that MENK may be a potential drug for the treatment of GC.

Keywords: MENK, GC cells, OGFr, cell cycle, apoptosis

Introduction

Gastric cancer remains one of the most common cancers, despite the recent decline in its incidence and mortality rates.1 In spite of diagnostic and therapeutic advances, which have provided significant survival benefit, gastric cancer is usually diagnosed at an advanced stage and clinical outcomes remain gloomy, which are attributed to a lack of early clinical symptoms and limited advances in our knowledge of disease pathogenesis.1,4 Therefore, there is an urgent need to elucidate the molecular events regulating the development of gastric cancer and to identify novel molecular targets for early screening and new therapeutic agents.

Methionine enkephalin (MENK) is an endogenous opioid pentapeptide derived from the adrenogenic prohormone proenkephalin, which is also known as opioid growth factor (OGF).5,6 This OGF is the native ligand for the opioid receptor (opioid growth
factor receptor (OGFr) or ζ-opioid receptor). The OGFr is a non-canonical, perinuclear opioid receptor that does not share structural homology with the canonical mu, kappa, and delta opioid receptors (OPRM, OPRK, and OPRD, respectively) and binds the native opioid ligand less efficiently than the canonical opioid receptors. The OGFr not only has neuroendocrine and immune regulation activity, but also has direct antitumor activity following binding to opioid receptors. Naltrexone (NTX), an opioid receptor antagonist, can inhibit the effects of MENK during co-incubation, supporting its role in the bioactivity of MENK. Data from previously published results from our laboratory indicated that MENK, in a dose-dependent manner, can inhibit tumor growth in vivo and in vitro. These studies have focused on human melanoma cancer, human pancreatic cancer, human ovarian cancer, thyroid follicular cell-derived cancers, human hepatocellular cancer, and triple-negative breast cancer. Our team has also demonstrated that MENK can inhibit human melanoma cancer cell growth by inducing cell apoptosis and cell cycle arrest in G0/G1 phase.

However, the effect of MENK and its potential molecular mechanisms on human gastric cancer cells in vitro and in xenograft experiments in vivo remain unknown. Therefore, we conducted the following investigations to examine the impact of MENK on gastric cancer.

Materials and methods

Cell line
Human gastric cancer cell lines SGC7901 and HGC27 were kind gifts from Professor Minjie Wei at the Department of Pharmacology, China Medical University. The two cell lines were purchased from Shanghai Genechem Co., Ltd. (Shanghai, China). Human gastric mucosal epithelial cell (GES-1) was purchased from FuHeng Cell Center (Shanghai, China). Cells were maintained in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA) culture medium containing 10% fetal calf serum (Thermo Fisher Scientific), 100 µg/mL streptomycin, and 100 U/mL penicillin under a humidified atmosphere containing 5% CO2 at 37°C. The cells in the exponential growth phase were used for our experiments.

MENK treatment
MENK (≥99% purity) was provided by American Peptide Co. (Sunnyvale, CA, USA). NTX (≥99.6% purity) was obtained from Sanofi-Aventis, Inc. (Paris, France). For cell proliferation testing, SGC7901 and HGC27 cells were incubated with MENK (0.5, 1, 2, 5, 10, 12.5 mg/mL) for 24, 48, 72 and 96 h, and pretreated with NTX (100, 200 and 300 nM) for 2.5 h followed by exposure to MENK (5 mg/mL) for 48 hours. The SGC7901 and HGC27 cells were treated with MENK (5 mg/mL) for 10 days in the colony-forming assay and treated for 48 hours for morphologic observation, Hoechst 33258 staining, cell cycle analysis, apoptosis analysis, quantitative real-time-PCR (qRT-PCR) analysis, and Western blot experiments. During in vivo experiments, MENK was dissolved in normal saline prior to injecting.

Cell proliferation inhibition assay
The Cell Counting Kit-8 assay kit (Dojindo Molecular Technologies, Tokyo, Japan) assay was used to determine the effect of MENK on cell proliferation according to the manufacturer’s instructions. SGC7901 and HGC27 cells were cultured at a density of 5,000 cells and 2,000 cells, respectively, in 96-well plates and exposed to MENK or NTX (alone or in combination) at the predetermined concentrations. After culture for 24, 48, 72, and 96 hours, Cell Counting Kit-8 was added to each well and the plates were incubated for another 2 hours. The absorbance value (OD) was read at 450 nm using a microplate reader (Bio-Rad Laboratories Inc., Hercules, CA, USA), and data were analyzed by GraphPad Prism software. Each experiment was performed in triplicate. Cell proliferation inhibition rate = 1 – (OD of treated group – OD of background)/(OD of control group – OD of background)×100%, and the best fitting line was used to obtain the estimated IC50 value from the concentration that could provide 50% reduction of cell proliferation. We also tested the effect of MENK on GES-1 cells.

Cell morphology observation
SGC7901 and HGC27 cells were treated with 5 mg/mL MENK for 48 hours and morphology changes were observed using light microscopy (Philips CM 100; Philips, Tokyo, Japan).

Colony-forming assay
SGC7901 and HGC27 cells in each group were seeded in six-well plates at a density of 300 or 350 cells per well and evenly mixed. After 24 hours of incubation, the cells were treated with 5 mg/mL of MENK alone or in combination with 200 nM NTX, renewing the medium every 4 days. After incubation for 10 days, the cells were fixed with 4% methanol for 15 minutes, washed twice with PBS, air dried, stained with crystal violet for 20 minutes, which was removed and
the plates were washed twice with PBS. Following drying, photographs were taken and the colonies with >10 cells were counted. Colony-forming efficiency = (number of colonies/ number of inoculated cells)×100%.

**Cell cycle analysis**

The cells of each group were collected and washed twice with ice-cold PBS; 10⁶ cells were fixed in precooled 70% ethanol for 2 hours at 4°C, centrifuged at 2,000 rpm, and the supernatant was discarded. Then 100 µL RNase A was added to each tube and incubated at room temperature for 30 minutes. Following incubation with RNase A, 400 µL of propidium iodine (PI) was added and the cells were incubated in the dark at room temperature for 30 minutes. The stained cells were analyzed by flow cytometry (BD, Franklin Lakes, NJ, USA), and the percentages of the nuclei in SGC7901 and HGC27 cells at each phase of the cell cycle (G0/G1, S, G2/M) were calculated.

**Cell apoptosis analysis**

Cellular apoptosis was determined by flow cytometry using the Annexin V-fluorescein isothiocyanate/PI kit (KeyGEN, Nanjing, China). The cells, after treatment for 48 hours with 5 mg/mL MENK, were trypsinized, centrifuged, and washed twice with precool PBS. The cells were resuspended in 1X binding buffer, and 1×10⁶ cells (100 µL) were incubated with 5 µL PI and 5 µL Annexin V for 15 minutes at room temperature in the dark. Within 1 hour, cell apoptosis was tested using flow cytometry (BD).

**Detection of apoptotic nuclei by Hoechst 33258 staining**

Hoechst 33258 staining was used to observe the nuclei morphology of apoptotic cells after treatment with 5 mg/mL MENK.²⁵ After treatment, the cells were fixed with 4% formaldehyde, washed three times with PBS, stained with 500 µL Hoechst 33258 (Sigma, Shanghai, China) for 10 minutes in the dark, and rinsed twice. Then, the cells were immediately observed under a fluorescence microscope (Olympus, Tokyo, Japan). The cells with condensed chromatin or fragmented nuclei were counted as apoptotic cells, and at least ten random fields including 400 cells were collected and quantified for each experiment. The data are shown as apoptotic percentage = apoptotic cells/total cells×100%.

**Western blotting**

The cells in each group were homogenized using a homogenizer (POLYTRON PT2100; Kinematic, Luzern, Switzerland) with ice-cold lysis buffer containing 1 mM phenylmethylsulfonyl fluoride to extract total protein. The proteins were separated on 10% SDS-PAGE²⁶ and transferred to nitrocellulose membrane. After being blocked, the transferred proteins were incubated with relevant antibodies against OGFr (1:1,000; Sigma), Bax, BCL-2, caspase-3, P ARP , β-actin (all above 1:1,000; Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C. After rinsing three times, the membranes were incubated with a secondary antibody (1:10,000; Cell Signaling Technology) for 1 hour at room temperature. Finally, bands were detected by chemiluminescence (Bio-Rad Laboratories Inc.) and quantified with ImageJ software. Band intensities were normalized to β-actin before expressing them as fold increase compared with that in the control group.

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5′–3′)</th>
<th>GC (%)</th>
<th>Tm (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OGFr</td>
<td>TCTGCCAGAACCAGGATGAAC</td>
<td>54.5</td>
<td>59.4</td>
</tr>
<tr>
<td></td>
<td>ATCCCGTAGAACCCGACA</td>
<td>57.9</td>
<td>59.1</td>
</tr>
<tr>
<td>Caspase-3</td>
<td>TGGCTCTGAGCCATGTGGA</td>
<td>50.0</td>
<td>56.8</td>
</tr>
<tr>
<td></td>
<td>TGGCAAAAGCGACTGAGT</td>
<td>52.6</td>
<td>57.4</td>
</tr>
<tr>
<td>BCL-2</td>
<td>GGTGGGGTCACTGTGTTGGA</td>
<td>63.2</td>
<td>59.5</td>
</tr>
<tr>
<td></td>
<td>CGGTTCAGGATCTCAGTCATCC</td>
<td>54.5</td>
<td>57.4</td>
</tr>
<tr>
<td>Bax</td>
<td>CCCGAGAGTCTTTTTCCGAG</td>
<td>57.1</td>
<td>58.1</td>
</tr>
<tr>
<td></td>
<td>CCAGCCCATGTGTTGTCGAT</td>
<td>52.4</td>
<td>57.5</td>
</tr>
<tr>
<td>Survivin</td>
<td>TTCTCAGGACCCCGCGA</td>
<td>52.6</td>
<td>56.8</td>
</tr>
<tr>
<td></td>
<td>CAACCCGACGATCTGCTTGTA</td>
<td>45.0</td>
<td>53.8</td>
</tr>
<tr>
<td>Ki67</td>
<td>ACTTGCTCTCCTAAAGCC</td>
<td>52.6</td>
<td>54.6</td>
</tr>
<tr>
<td></td>
<td>TTACTACATCTGCCCATGA</td>
<td>42.1</td>
<td>49.5</td>
</tr>
<tr>
<td>Cyclin D1</td>
<td>AGCTCCCTGTCGCGAAGTGGAAC</td>
<td>56.0</td>
<td>64.4</td>
</tr>
<tr>
<td></td>
<td>AGTTGCTAATGAAACTCGTGCGG</td>
<td>48.0</td>
<td>61.3</td>
</tr>
<tr>
<td>C-myc</td>
<td>CTCTCTCGGTCCCTGGATTCT</td>
<td>54.5</td>
<td>58.4</td>
</tr>
<tr>
<td></td>
<td>GAAGTTGATCCAGACTCTGACCTT</td>
<td>50.0</td>
<td>58.3</td>
</tr>
<tr>
<td>β-Actin</td>
<td>AGCGACGATCCCCAAGTTT</td>
<td>55.0</td>
<td>59.9</td>
</tr>
<tr>
<td></td>
<td>GGGACGAAGGCTCATCATT</td>
<td>55.0</td>
<td>58.4</td>
</tr>
</tbody>
</table>

Abbreviation: GC, gastric cancer.

as listed in Table 1. Each qRT-PCR reaction mixture contained 10 µL SYBR, 6 µL ddH₂O, 0.8 µL forward primer, 0.8 µL reverse primer, 0.4 µL ROX II, and 2 µL cDNA. The qRT-PCR reaction conditions were as follows: 95°C pre-degeneration for 3 minutes, followed by 40 cycles of 95°C degeneration for 5 seconds, 60°C for 34 seconds, and 72°C extension for 30 seconds. The reaction system was performed using 7500 Real-Time PCR System (Thermo Fisher Scientific). β-Actin was used as an internal reference and the cycle threshold (Ct) value was used to calculate relative gene expression based on 2−ΔΔCt.
### Xenograft experiments with nude mice
All animal experiments were carried out according to the Guide for the Animal Welfare and Ethics Committee of China Medical University (Shenyang, China), and the present study was approved (approval Institutional Animal Care and Use Committee no. 2018075). Female BALB/c nude mice (4–6 weeks old) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Exactly $10^6$ SGC7901 cells in a volume of 100 µL were administered subcutaneously into the right head and neck region of mice. When the average size of the tumors reached $80 \text{ mm}^3$, the mice were randomly separated into four groups: MENK group (5, 8, 10 mg/2 days; n=5 per group) and the control group (normal saline, n=5). Tumor size was measured using calipers every third day, and tumor volume was calculated based on the following formula: volume ($\text{mm}^3$) = $(\text{length} \times \text{width}^2)/2$. Tumor growth was observed for 22 days from the first treatment until the tumors reached $-900 \text{ mm}^3$ in total volume. Body weights were also recorded every third day. After 22 days, the mice were euthanized according to the institutional guidelines; the tumors were removed and weighed as previously reported.27,28

### Histology and immunohistochemistry
The tumors from nude mice were fixed in 4% paraformaldehyde for 24 hours, dehydrated in an alcohol gradient, paraffin-embedded, and cut into 4 µm sections. After deparaffinization with xylene and rehydration, paraffin-embedded sections were subjected to H&E staining and immunohistochemistry according to a standard protocol.6 Primary antibodies against OGFr (1:100; Proteintech, Wuhan, China) and Ki67 (1:400; Cell Signaling Technology) were used. Each slide was incubated at 4°C overnight with a primary antibody, washed, and then incubated for 1 hour at room temperature with the secondary antibody. Sections were stained with diaminobenzidine and the nucleus was counterstained with hematoxylin. Finally, neutral gum was used for sealing the stained sections and the images were observed under a light microscope (Olympus).

### TUNEL assays
Paraffin-embedded tissues were cut into sections and TUNEL assays were performed using a detection kit (Wanlei Biotechnology, Shenyang, China) according to the manufacturer’s instruction. Following this, the sections were stained with diaminobenzidine and counterstained with hematoxylin.

### Statistical analysis
All data are presented as mean±SD, analyzed by GraphPad Prism software. The differences between groups were evaluated by Student’s t-test for two groups and by one-way ANOVA for multiple groups. The result was considered significant when $P<0.05$.

### Results

#### Effect of MENK on cell proliferation
The cell proliferation of SGC7901 and HGC27 cells was decreased by MENK in a dose- and time-dependent manner. The $IC_{50}$ of MENK on SGC7901 cells was 13.45 mg/mL at 24 hours, 5.95 mg/mL at 48 hours, 4.95 mg/mL at 72 hours, and 3.94 mg/mL at 96 hours (Figure 1A1; Table 2). The $IC_{50}$ of MENK on HGC27 cells was 12.92 mg/mL at 24 hours, 8.75 mg/mL at 48 hours, 3.04 mg/mL at 72 hours, and 2.48 mg/mL at 96 hours (Figure 1A2; Table 2). Compared with the control group at the same time, the inhibition of proliferation of SGC7901 cells by 5 mg/mL of MENK was 23.04%±4.00% at 24 hours, 35.34%±6.53% at 48 hours, 46.37%±4.68% at 72 hours, and 52.05%±3.71% at 96 hours, and of HGC27 cells was 13.18%±4.00%, 21.40%±7.58%, 48.18%±4.66%, and 58.63%±2.88%, respectively ($P<0.05$; Table 3). This effect of MENK could be blocked by NTX at a concentration of 200 nM. Compared with the control (RPMI 1640) group, the inhibitory activity of MENK or MENK with one of three different NTX concentrations (100, 200, 300 nM) on SGC7901 cells was 44.05%±5.77%, 12.33%±2.08%, 9.53%±2.31%, and 18.97%±4.39%, respectively. Similar results were obtained with HGC27 cells using the same drug concentration, which showed inhibition of 29.50%±5.77%, 26.57%±4.64%, 16.70%±3.10%, and 17.57%±2.48%, respectively ($P<0.05$; Figure 1B1 and B2). Compared with the control group, MENK had no significant effect on normal human GES-1 proliferation ($P>0.05$; Figure 1C1 and C2).

#### Effect of MENK on cell colony formation
After treatment with MENK, the number of colonies of SGC7901 cells decreased from $330±25$ (RPMI 1640 group) to $215±22$ (MENK group). Meanwhile, the difference between MENK group and MENK+NTX group (290±26) was significant. Similarly, the number of colonies of HGC27 cells decreased from $271±25$ (RPMI 1640 group) to $166±35$ (MENK group), and the difference between MENK group and MENK+NTX group (239±36) made sense ($P<0.05$; Figure 2A1–A3).
**MenK induced cell cycle arrest and apoptosis in gC cells**

**Figure 1** Effect of MenK on cell growth in vitro.

**Notes:** The effect of MenK on SGC7901 and HGC27 cells (A) and the blocking effect of nTX (B) were measured by CCK-8 test. Both SGC7901 (A1) and HGC27 (A2) treated with 1, 2, 5, 10, 12.5 mg/mL of MenK showed significant reduction in cell proliferation. A plateau was observed at 12.5 mg/mL, and 0.5 mg/mL MenK showed no effect (*P* < 0.05, compared with that in the control group; Δ*P* < 0.05, compared with that for 24 hours; #*P* < 0.05, compared with that for 48 hours; ∇*P* < 0.05, compared with that for 72 hours). The SGC7901 (B1) and HGC27 (B2) cells were pretreated with nTX (100, 200, 300 nM, respectively) for 2.5 hours before treating them with 5 mg/mL MenK for 48 hours. in all graphs, data are mean±SD of more than three independent experiments (*P* < 0.05, **P** < 0.01, ***P** < 0.001).

**Abbreviations:** CCK-8, Cell Counting Kit-8; GES-1, human gastric epithelial cell line; MenK, methionine enkephalin; nTX, naltrexone.
Table 2: The IC_{50} of MENK on the cell proliferation of human gastric cancer cells

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Classification</th>
<th>IC_{50} (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>SGC7901</td>
<td>Gastric cancer cells</td>
<td>13.45</td>
</tr>
<tr>
<td>HGC27</td>
<td>Gastric cancer cells</td>
<td>12.92</td>
</tr>
</tbody>
</table>

Abbreviation: MENK, methionine enkephalin.

Table 3: The inhibitory rate of 5 mg/mL MENK on human gastric cancer cells

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Classification</th>
<th>Inhibitory rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>SGC7901</td>
<td>Gastric cancer cells</td>
<td>23.04±2.09</td>
</tr>
<tr>
<td>HGC27</td>
<td>Gastric cancer cells</td>
<td>13.18±4.00</td>
</tr>
</tbody>
</table>

Abbreviation: MENK, methionine enkephalin.

Figure 2: Effect of MENK on cell colony formation and cell morphology of SGC7901 and HGC27 cells in vitro.

Notes: (A1–A3) The colony formation assay was assessed after culturing cells for 10 days. Representative images and statistical analyses showed that MENK inhibited cell colony formation by SGC7901 and HGC27 cells (P<0.05). (B1, B2) The morphology changes of SGC7901 and HGC27 cells before and after treatment with 5 mg/mL MENK for 48 hours (200×). In all graphs, data are mean±SD of more than three independent experiments (*P<0.05, **P<0.01, ***P<0.001).

Abbreviations: MENK, methionine enkephalin; NTX, naltrexone.

Effect of MENK on cell morphology

SGC7901 and HGC27 cells were cultured in the presence of 5 mg/mL MENK for 48 hours and the cell morphology was observed by light microscopy (Figure 2B1 and B2). The results demonstrated that the appearance of the cells, after treatment with MENK, changed from polygonal,
cobblestone-like cells into a fusiform-like, weakly adherent cellular morphology with an accompanying reduction in cell numbers. In addition, a few cells were observed to be deformed, increased in size, or nonadherent.

**Effect of MENK on cell cycle**

After treatment with 5 mg/mL MENK, both SGC7901 and HGC27 cells demonstrated higher numbers of cells in the G1 phase and lower cell counts in the S phase vs those in the control group. The cell ratios at the G0/G1 phase for SGC7901 and HGC27 cells in the MENK group were 58.1±2.1 and 57.9±3.0, respectively, vs 42.3±1.7 and 43.24±2.4, respectively, in the RPMI 1640 group, and the difference between the two groups was significant (P<0.05). The cell ratios at the S phase for SGC7901 and HGC27 cells in the MENK group were 15.98±1.8 and 19.85±2.7, respectively, vs 29.4±±1.9 and 30.85±2.6, respectively, in the RPMI 1640 group, and the difference between the two groups was significant (P<0.05). This effect could be blocked by NTX (P<0.05; Figure 3A–C).

**Effect of MENK on cell apoptosis**

Both SGC7901 and HGC27 cells were stained with Annexin V-fluorescein isothiocyanate/PI and analyzed by flow cytometry. The results indicated that the percentage of early apoptotic cells (lower right quadrant) in the MENK group increased significantly vs that in the control group (P<0.05). The percentage of late apoptotic cells (upper right quadrant) in the MENK group was also much higher (P<0.01) than that in the control group (Figure 4A1–A3).

In addition, the changes in nuclear morphology of SGC7901 and HGC27 cells were analyzed under a fluorescence microscope by Hoechst 33258 staining. The nuclei of the MENK-treated cells showed chromatin condensation and nuclear shrinkage (Figure 4B1 and B2). These results indicated that MENK induced apoptosis of SGC7901 and HGC27 cells.

**Effect of MENK on OGFr expression by SGC7901 and HGC27 cells**

The OGFr is the native ligand for the OGF (MENK). After treatment with MENK, mRNA levels of OGFr in SGC7901 and HGC27 cells increased 5.04- and 7.83-fold, respectively (P<0.01; Figure 5Ah) and the protein levels of OGFr in both cells as assessed by Western blot also showed a 3.45- and 2.14-fold increase (P<0.01; Figure 5Be). Furthermore, SGC7901 tumors in xenograft nude mice treated with MENK had an increased expression of OGFr on immunohistochemistry. These results confirm that MENK can increase the expression of OGFr in tumor cells in vivo (P<0.05; Figure 6F1 and F2) and suggest that MENK may suppress tumor growth by regulating OGFr expression.

**Effect of MENK on the expression of cell cycle-related genes Ki67, cyclin D1, c-myc**

To investigate the effect of MENK on the cell cycle phase of SGC7901 and HGC27, the expression of Ki67, cyclin D1, and c-myc in each group was detected by qRT-PCR. Compared to the control group, MENK decreased the mRNA level of Ki67 (0.23-fold, P<0.01), cyclin D1 (0.62-fold, P<0.01), and c-myc (0.50-fold, P<0.01) in SGC7901 cells. Similarly, compared to the control group, the mRNA levels of Ki67 (0.45-fold, P<0.01), cyclin D1 (0.57-fold, P<0.01), and c-myc (0.66-fold, P<0.01) were reduced in HGC27 cells with MENK treatment (P<0.05; Figure 5Aa–c). Confirmation of these observations was done with in vivo studies of the expression of Ki67, a marker of cell proliferation and cell cycle progression that was detected with immunochemistry in sections from randomly selected xenograft nude mice tumors. Ki67 expression was clearly localized within the nucleus and it was significantly suppressed by MENK (P<0.05; Figure 6F1 and F2).

**Effect of MENK on the expression of apoptosis-related genes—proteins bax, BCL-2, caspase-3, PARP, and survivin in SGC7901 and HGC27**

Furthermore, qRT-PCR and Western blots were used to examine apoptosis-related genes and their proteins. The qPCR results demonstrated that, with SGC7901 and HGC27 cells, MENK downregulated the mRNA levels of BCL-2 (0.39- and 0.67-fold, respectively; P<0.01) and survivin (0.49- and 0.67-fold, respectively; P<0.01) and c-myc (0.66-fold, P<0.01) and the protein expression of BCL-2 (0.37- and 0.75-fold, respectively; P<0.01) and survivin (0.49- and 0.67-fold, respectively; P<0.01) were reduced in HGC27 cells with MENK treatment (P<0.05; Figure 5Aa–c). Confirmation of these observations was done with in vivo studies of the expression of Ki67, a marker of cell proliferation and cell cycle progression that was detected with immunochemistry in sections from randomly selected xenograft nude mice tumors. Ki67 expression was clearly localized within the nucleus and it was significantly suppressed by MENK (P<0.05; Figure 6F1 and F2).

**Therapeutic effect of MENK on suppressing tumor growth of SGC7901 in xenograft nude mice**

The effect of MENK on tumor growth in vivo was evaluated using a xenograft model and the results showed that
tumors in the MENK treatment group were significantly smaller following 22 days of administration (*P*<0.05; Figure 6A). Consistent with this observation, the tumor weights from the MENK treatment group at euthanasia were significantly less, compared with those in the control group (*P*<0.05; Figure 6B). Both studies revealed that
Figure 4 Effect of MENK on apoptosis and apoptotic morphology of SGC7901 and HGC27 cells in vitro.
Notes: (A1, A2, A3) Apoptosis was measured by flow cytometry using an Annexin V-FITC/PI kit. The percentage of early apoptotic cells (AV+/PI–, P<0.05) and late apoptotic cells (AV+/PI+, P<0.01) in the MENK-treated group increased significantly vs those in the control group. Also, the percentage of viable cells decreased accordingly (AV–/PI–, P<0.01). The percentage of early apoptotic cells (AV+/PI–, P<0.05) of HGC27 cells and the percentage of late apoptotic cells (AV+/PI+, P<0.05) of both cell lines in the MENK+NTX group decreased significantly vs those in the MENK-treated group. Similarly, the percentage of viable cells increased accordingly (AV–/PI–, P<0.01). (B1, B2) Fluorescence micrographs of SGC7901 and HGC27 cells stained with Hoechst 33258 (100×). The cells treated with 5 mg/mL MENK and 5 mg/mL MENK combined 200 nM NTX for 48 hours showed that MENK induced apoptosis in SGC7901 cells, characterized by nuclear condensation or nuclear fragmentation. In all graphs, data are represented as mean±SD of more than three independent experiments (*P<0.05, **P<0.01, ***P<0.001).

Abbreviations: FITC, fluorescein isothiocyanate; MENK, methionine enkephalin; NTX, naltrexone; PI, propidium iodide.
Figure 5 Effect of MenK on the expression of OgFr, cell cycle, and apoptosis-related genes/proteins of SGC7901 and HGC27 after MenK treatment in vitro.

Notes: (Ah) After treatment with MenK and MenK+NTX for 48 hours, the OgFr mRNA expression in SGC7901 and HGC27 cells was determined by qRT-PCR. (Aa–c) The mRNA expression levels of cell cycle-related genes such as Ki67, cyclin D1, and c-myc. (Ad–g) The mRNA expression of the apoptosis-related genes Bax, BCL-2, caspase-3, and survivin. (B) In addition, whole cell lysates from both gastric cancer cells after treatment with MenK or MenK+NTX for 48 hours in vitro were immunoblotted for OgFr and apoptosis-related proteins (Bax, BCL-2, cleaved caspase-3, cleaved PARP). (a–e) The numbers represent normalized band intensities after comparison with β-actin levels for all proteins. For all experiments, results represent the average±SD of three independent samples (*P<0.05, **P<0.01, ***P<0.001).

Abbreviations: MenK, methionine enkephalin; NTX, naltrexone; qRT-PCR, quantitative real-time-PCR.
Figure 6 (Continued)
MENK could delay tumor growth in a dose-dependent manner (Figure 6C). As a measure of toxicity, MENK treatment did not affect body weight during the experiment (Figure 6D). In summary, in these xenograft experiments, MENK suppressed tumor growth on using a subcutaneous tumor model.

Histopathologic morphology of tumors

The results of the histopathology analysis revealed that posttreatment with MENK, there were large areas of central necrosis in the MENK-treated tumors, accompanied by apoptosis, hyperchromatic nuclei, and tumor cells with relatively small amount of cytoplasm. Binuclear or multinuclear giant cells were also observed in some tumors, while the morphology of tumor cells in the control group was regular and compact, with a few punctate or scattered necrotic regions among the tumor parenchyma (Figure 6E). These results demonstrated that MENK could control tumor growth of SGC7901 tumor cells in nude mice by inducing the apoptosis of tumor cells. The apoptosis indices of SGC7901 tumors as measured by TUNEL analysis for control and MENK-treated groups were 6.20% and 15.27% ($P<0.05$), respectively (Figure 6G1 and G2).

Discussion

MENK, at a suitable range of concentrations and in a dose- and time-dependent manner, had an anticancer effect that was associated with binding to opioid receptors. MENK can also regulate macrophage functions, as well as the functions of dendritic cells, CD8+ T cells, CD4+ T cells, and natural killer cells as an immune regulator. Published data suggest that MENK also has an antiviral role during influenza and...
HIV infections. Moreover, MENK has significant immunotherapeutic activity against tumors in vivo, including ovarian, pancreatic, and head–neck cancers, and can inhibit or delay tumor cell proliferation directly in vitro through cell apoptosis and/or cell cycle arrest, as reported in studies examining human melanoma, triple-negative breast cancer, and hepatoblastoma cancer cells. The results from all these studies support these bioactivities mediated by OGrFr ligation.

In the present study, we explored the effects and mechanisms of MENK on human gastric cancer. These studies used two cell lines of human gastric cancer SGC7901 and HGC27 and revealed that MENK could act in a dose- and time-dependent manner, measured as the inhibition of tumor cell growth, with a decrease in cell colonies and changes in cell morphology from polygonal, cobblestone-like into fusiform-like, weakly adherent cells. Our studies also demonstrated that MENK induced SGC7901 and HGC27 cell apoptosis in vitro and in vivo, as evidenced by the increased apoptotic ratio and obvious apoptotic characteristics, such as condensed chromatin and nuclear shrinkage, which was supported by Hoechst DNA staining analysis. In addition, the cells in the MENK-treated group showed cell cycle arrest in the G0/G1 phase.

Our studies reported herein also examined the mechanisms through which MENK suppressed the cell growth of human gastric cancer cells. We confirmed the expression of OGrFr on SGC7901 and HGC27 cells and also found that MENK treatment could increase the expression of OGrFr, and that this action could be blocked by NTX, which correspondingly blocked the antitumor effect of MENK, including induction of cell apoptosis and arrest of cell cycle in G0/G1 by SGC7901 and HGC27 cells.

The cell cycle arrest differed from the finding of Cheng et al, which reported that MENK induced cell proliferation in diverse human cancers by targeting a p21/p16 cyclin-dependent kinase inhibitory pathway. In our studies, we examined the mRNA expression of cyclin D1 and c-myc, which are targets of the Wnt/β-catenin signaling pathway, and cyclin D1, which is also known to regulate cell cycle arrest at G0/G1 phase. We observed that MENK induced G0/G1 arrest, as evidenced by the decreased mRNA expression of cyclin D1 and c-myc in vitro which is involved in cell cycle regulation – a result that differs from Cheng’s study. Thus, we speculate that MENK may have a regulating role in genes associated with cell cycle regulation and the inhibition of Wnt/β-catenin signaling pathway. Both qRT-PCR and immunohistochemistry analyses revealed the regulation of Ki67 expression in vitro and in vivo, which suggests that this inhibition occurs before Ki67 protein synthesis. In other words, MENK could retard cell proliferation by activating proliferation-related signal transduction pathways.

When a tumor cell is stimulated by an apoptosis inducing factor, for instance, oncogene activation, DNA damage, cell hypoxia, or cell growth factor deletion, the factor can then activate the mitochondrial apoptosis pathway, leading to cell apoptosis. Caspase-3 is a critical mediator in cell apoptosis and its activation is regulated by the BCL-2 family, which includes the antiapoptosis genes (BCL-2, BCL-xl) and the proapoptosis genes (Bax, BCL-xs). PARP, an enzyme that is involved in DNA repair, is one of the main substrates of activated caspase-3. Our Western blot data showed that MENK treatment resulted in an increase in Bax, cleaved caspase-3, and cleaved PARP protein levels, with a concomitant decrease in the BCL-2 protein levels in SGC7901 and HGC27 cells in vitro. The increased Bax/BCL-2 ratio and caspase-3 together with its main substrate PARP supports our hypothesis that the caspases and BCL-2 family play regulating roles in the process of MENK-induced apoptosis.

Survivin gene expression is also a mediator of apoptosis resistance and cell cycle progression in gastric cancer cells. Survivin is also identified as a “survival factor”, which is attributed to its ability to inhibit apoptosis and support the growth of tumor cells. In the present study, the survivin mRNA levels were reduced 0.011-fold after MENK treatment of SGC7901 and HGC27 cells in vitro, which suggested that MENK may induce apoptosis by downregulating survivin expression.

Despite the fruitful results obtained above, we have not yet touched the more complicated signal mechanisms such as relation of change in mitochondria membrane to cell apoptosis. Therefore, more detailed study is required to clarify the cellular signaling process through which MENK induces cell cycle and apoptosis in gastric cancer and the effects of MENK on other biological characteristics in gastric cancer, including invasion, metastasis, and epithelial–mesenchymal transition.

Conclusion
These studies have extended our understanding of the effect of MENK on gastric cancer using a xenograft model in nude mice. Compared to the control group, the tumor growth was slowed after initiation of treatment with MENK in a dose- and time-dependent manner, which was consistent with our in vitro experiments. Further, H&E and TUNEL staining supported induction of apoptosis by MENK in vivo. In conclusion, the morphologic and biochemical studies demonstrate

For personal use only.
that MENK has anticancer activity in SGC7901 and HGC27 cells by arresting the cell cycle at G0/G1 phase and inducing apoptosis both in vitro and in vivo. Our results also support a relationship between MENK-induced cell cycle regulation and the Wnt/β-catenin signaling pathway. Moreover, the induction of apoptosis was closely associated with the BCL-2/Bax/caspase-3/PARP signaling. These results provide useful mode of action and reveal concrete mechanisms of MENK, which will enrich our understanding of the opioid receptor-mediated anticancer activity by MENK.

Acknowledgments

This work was supported financially by China National Funding for Natural Science (31670921 to Fengping Shan) and China Liao ning Province Supporting Construction of Discipline Platforms in Universities. Thanks for the other researchers who have also contributed significantly to this study.

Disclosure

Noreen Griffin is a Founder, CEO, and a member of the Board of Directors for Immune Therapeutics Inc. Fengping Shan is the Chief Scientific Officer for Immune Therapeutics Inc. and has patents on naltrexone that have been licensed to Immune Therapeutics Inc. The authors report no other conflicts of interest in this work.

References